AbbotJ. D.,
JonesD. M.,
PainterM. J.,
YoungS. E. J.1985; The epidemiology of meningococcal infection in England and Wales 1912–1983. Journal of Infection 11:241–257
AbdillahiH.,
CroweB. A.,
AchtmanM.,
PoolmanJ. Two monoclonal antibodies which recognize the serotype 4 antigen of Neisseria meningitidis. European Journal of Clinical Microbiology in press
AbdillahiH.,
PoolmanJ. T.,
HopmanC. T. P.,
ZanenH. C.1986; Sero- and subtyping of non-2a, non-2b and non-15 group B Neisseria meningitidis. Antonie van Leeuwenhoek 52:242–244
AchtmanM.1988; Purification and characterization of eight class 5 outer membrane protein variants from a clone of Neisseria meningitidis serogroup A. Journal of Experimental Medicine in press
BarlowA. K.,
HeckelsJ. E.,
ClarkeI. N.1987; Molecular cloning and expression of Neisseria meningitidis class 1 outer membrane protein in Escherichia coli K-12. Infection and Immunity 55:2734–2740
BarrittD. S.,
SchwalbeR. S.,
KlapperD. G.,
CannonJ. G.1987; Antigenic and structural differences among six proteins II expressed by a single strain of Neisseria gonorrhoeae. Infection and Immunity 55:2026–2031
BeuveryE. C.,
MiedemaF.,
van DelftR.,
HaverkampJ.1983; Preparation and immunochemical characterization of meningococcal group C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines. Infection and Immunity 40:39–45
BlackwellC. C.,
JonsdottirK.,
MohammedJ.,
WeirD. M.1986; Non-secretion of blood group antigens: a genetic factor predisposing to infection by Neisseria meningitidis. Proceedings of the fifth international pathogenic neisseria conference V p 106
BlakebroughI. S.,
GillesH. M.1980; The effect of rifampicin on meningococcal carriage in family contacts in northern Nigeria. Journal of Infection 2:137–143
BlakebroughI. S.,
GreenwoodB. M.,
WhittleH. C.,
BradleyA. K.,
GillesH. M.1982; The epidemiology of infections due to Neisseria meningitidis and Neisseria lactamica in a northern Nigerian community. Journal of Infectious Diseases 146:626–637
CaugantD. A.1986a; Multilocus genotypes determined by enzyme electrophoresis of Neisseria meningitidis isolated from patients with systemic disease and from healthy carriers. Journal of General Microbiology 132:641–652
CaugantD. A.1986b; Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proceedings of the National Academy of Sciences of the USA 83:4927–4931
CaugantD. A.,
MoccaL. F.,
FraschC. E.,
FroholmL. O.,
ZollingerW. D.,
SelanderR. K.1987; Genetic structure of Neisseria meningitidis populations in relation to serogroup, and outer membrane protein pattern. Journal of Bacteriology 169:2871–2792
de LemosR. A.,
HaggertyR. J.1969; Corticosteroids was an adjunct to treatment in bacterial meningitis: a controlled clinical trial. Pediatrics 44:30–34
DensenP.,
WeilerJ. M.,
GriffissJ.,
HoffmanL. G.1987; Familial properdin deficiency and fatal meningococcaemia. New England Journal of Medicine 316:922–926
De WalsP.1981; Meningococcal disease in Belgium: secondary attack rate among household, day-care nursery, and pre-elementary school contacts. Journal of Infection 3: Suppl 153–61
EdwardsE. A.,
DevineL. F.,
SengbuschC. H.,
WardH. W.1977; Immunologic investigations of meningococcal disease: brevity of Group C acquisition prior to disease occurrence. Scandinavian Journal of Infectious Diseases 9:105–110
EskolaJ.1985; Antibody levels achieved in infants by course of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine. Lancet 1:1184–1186
FergusonJ. H.,
ChapmanO. D.1948; Fulminating meningococcic infections and the so-called Waterhouse-Friderichsen syndrome. American Journal of Pathology 24:763–796
FiliceG. A.,
HayesP. S.,
CountsG. W.,
GriffissJ. M.,
FraserD. W.1985; Risk of group A meningococcal disease: bacterial interference and cross-reactive bacteria among mucosal flora. Journal of Clinical Microbiology 22:152–156
FinneJ.,
LeinonenM.,
MakelaP. H.1983; Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2:355–357
FothergillL. D.,
WrightJ.1933; Influenzal meningitis: relation of age incidence to bactericidal power of blood against causal organism. Journal of Immunology 24:273–281
FraschC. E.1977; Role of protein serotype antigens in protection against disease due to Neisseria meningitidis. Journal of Infectious Diseases 136: (Suppl) S84–S90
FraschC. E.,
McNelisR. M.,
GotschlichE. C.1976; Strain-specific variation in the protein and lipopolysaccharide composition of the group B meningococcal outer membrane. Journal of Bacteriology 127:973–981
FraschC. E.,
CoetzeeG.,
ZahradrikD. M.,
WangL. K.1985a; New developments in meningococcal vaccines. In
SchoolnikG. K.
(ed) The pathogenic neisseriae American Society for Microbiology; Washington, DC: pp 633–639
FraschC. E.,
ZollingerW. D.,
PoolmanJ. T.1985b; Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Reviews of Infectious Diseases 7:504–510
FroholmL. O.1986; Preliminary results from a clinical trial with a meningococcal vaccine containing serotype 2b and 15 antigens in complex with mixed, A. C, K and W135 polysaccharides. Antonie van Leeuwenhoek 52:239–241
GoldschneiderI.,
GotschlichE. C.,
ArtensteinM. S.1969; Human immunity to the meningococcus. I. The role of humoral antibodies. Journal of Experimental Medicine 129:1307–1326
GotschlichE. C.,
AustrianR.,
CvjetanovicB.,
RobbinsJ. B.1978; Prospects for the prevention of bacterial meningitis with polysaccharide vaccines. Bulletin of the WHO 56:509–518
GotschlichE. C.,
GoldschneiderI.,
ArtensteinM. S.1969; Human immunity to the meningococcus IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. Journal of Experimental Medicine 129:1367–1384
GotschlichE. C.,
LiuT. Y.,
ArtensteinM. S.1969; Human immunity to the meningococcus. III. Preparation and immunochemical properties of the group, A. group, B. and group C meningococcal polysaccharides. Journal of Experimental Medicine 129:1349–1365
GreenwoodB. M.1987; Factors influencing susceptibility to meningococcal disease during an epidemic in The Gambia, West Africa. Journal of Infection 14:167–184
GreenwoodB. M.,
WhittleH. C.,
BrycesonA. D. M.1973; Allergic complications of meningococcal disease. II. Immunological investigations. British Medical Journal 269:737–740
GreenwoodB. M.,
WhittleH. C.,
Dominic–RajkovicO.1971; Counter-current immunoelectrophoresis in the diagnosis of meningococcal infections. Lancet 2:519–521
GriffissJ.,
BertramM. A.1977; Immunoepidemiology of meningococcal disease in military recruits. II. Blocking of serum bactericidal activity by circulating IgA early in the course of invasive disease. Journal of Infectious Diseases 136:733–739
HankinsW. A.,
GwaltneyJ. M.,
HendleyJ. O.,
FarquarJ. D.,
SamuelsonJ. S.1982; Clinical and serological evaluation of a meningococcal polysaccharide vaccine, Groups A, C, Y and W 135.. Proceedings of the Society for Experimental Biology and Medicine 169:54–57
HeckelsJ. E.,
VirjiM.1985; Monoclonal antibodies against gonococcal pili: uses in the analysis of gonococcal immunochemistry and virulence. In
de MacarioA. J. L.,
de MacarioE. C.
(eds) Monoclonal antibodies against bacteria vol I Academic Press Inc; New York: pp 1–35
HeistG. D.,
CohenS.,
Solis-CohenM.1922; A study of the virulence of meningococci for man and of human susceptibility to meningococcic infection. Journal of Immunology 7:1
JenningsH. J.,
RoyR.,
MichonP.1985; Determinant specificities of the groups B and C polysaccharides of Neisseria meningitidis. Journal of Immunology 134:2651–2657
JenningsH. J.,
GamianA.,
AshtonF. E.1987; N–propionylated group B meningococcal polysaccharide mimics a unique epitope on group B meningococci. Journal of Experimental Medicine 165:1207–1211
JonesD. M.,
EldridgeJ.,
SutcliffeE. M.1986; Emergence of group B type 15 strains as a cause of meningococcal infection in England and Wales. Antonie van Leeuwenhoek 52:206–207
KaiserA. B.,
HennekensC. H.,
SaslawM. S.,
HayesP. S.,
BennettJ. V.1974; Seroepidemiology and chemoprophylaxis of disease due to sulfonamide-resistant Neisseria meningitidis in a civilian population. Journal of Infectious Diseases 130:217223
KäyhtyH.,
KarankoV.,
PeltolaH.,
SamaS.,
MakelaP. H.1980; Serum antibodies to capsular polysaccharide vaccine of Group A Neisseria meningitidis followed for three years in infants and children. Journal of Infectious Diseases 142:861–868
MakelaP. H.1977; Polysaccharide vaccines of group A Neisseria meningitidis and Haemophilus influenzae type b: a field trial in Finland. Journal of Infectious Diseases 136: Suppl S43–S50
MargarettenW.,
CsavassyI.,
McKayD. G.1967; An electron microscope study of a case of meningococcemia in man. American Journal of Diseases of Children 114:268–277
Meningococcal Disease Surveillance Group1976; Meningococcal disease: secondary attack rate and chemoprophylaxis in the United States 1974. Journal of the American Medical Association 235:261–265
MoccaL. F.,
KarpasA. B.,
WuL. H.,
FraschC. E.1984; Functional activity of monoclonal antibodies against outer membrane surface antigens of Neisseria meningitidis. Proceedings of the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, p 295 (abstract)
NicholsonA.,
LepowJ. H.1979; Host defence against Neisseria meningitidis requires a complement-dependent bactericidal activity. Science 205:298–299
OlcenP.,
KjellanderJ.,
DaniellssonD.,
LindquistB. L.1981; Epidemiology of Neisseria meningitidis prevalence and symptoms from the upper respiratory tract in family members to patients with meningococcal disease. Scandinavian Journal of Infectious Diseases 13:105–109
OlyhoekT.,
CroweB. A.,
AchtmanM.1985; Epidemiological analyses of the geographical distribution of Neisseria meningitidis group A. In
SchoolnikG. K.
(ed) The pathogenic neisseriae American Society for Microbiology; Washington DC: pp 530–535
OlyhoekT.,
CroweB. A.,
AchtmanM.1987; The clonal population structure of Neisseria meningitidis serogroup A isolated from epidemics and pandemics between 1915 and 1983. Reviews of Infectious Diseases 9:665–692
OlyhoekT.,
CroweB. A.,
WallB.,
AchtmanM.1988; Comparison of clonal analysis and DNA restriction analysis for typing of Neisseria meningitidis. Microbial Pathogenesis 4:45–51
PeltolaH.1977; Clinical efficacy of meningococcal group A vaccine in children three months to five years of age. New England Journal of Medicine 297:686–691
PoolmanJ. T.,
de MarieS.,
ZanenH. C.1980; Variability of low-molecular-weight, heat-modifiable outer membrane proteins of Neisseria meningitidis. Infection and Immunity 30:642–648
PoolmanJ. T.,
HopmanC. T. P.,
ZanenH. C.1985a; Colony variants of Neisseria meningitidis strain 2996 (B: 2b: P12): influence of class-5 outer membrane proteins and lipopolysaccharides. Journal of Medical Microbiology 19:203–209
PoolmanJ. T.,
LindI.,
JonsdottirK.,
ForholmL. O.,
JonesD. M.,
ZanenH. C.1986; Meningococcal serotypes and serogroup B disease in North-West Europe. Lancet 2:555–558
PoolmanJ. T.,
WientjesF. B.,
HopmanC. T. P.,
ZanenH. C.1985b; Influence of the length of lipopolysaccharide molecules on the surface exposure of class 1 and 2 outer membrane proteins of Neisseria meningitidis 2996 (B: 2b: PI.2). In
SchoolnikG. K.
(ed) The pathogenic neisseriae American Society for Microbiology; Washington DC: pp 562–570
PoolmanJ. T.,
ZanenH. C.1980; Antibody development after meningococcal disease as measured by gel-immuno-radioassay (GIRA). In
DaniellssonD.,
NormarkS.
(eds) Genetics and immunobiology of pathogenic neisseria Umea University Press; pp 107–115
PoolmanJ. T.1987; Comparison of meningococcal outer membrane protein vaccines, solubilized with detergent or C polysaccharide. Antonie van Leeuwenhoek Si AM-AW
RossS. C.,
DensenP.1984; Complement deficiency states and infection; epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine 63:243–273
RossS. C.,
RosenthalP. J.,
BerberichH. M.,
DensenP.1987; Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. Journal of Infectious Diseases 155:1266–1275
SaukkonenK.,
AbdillahiH.,
PoolmanJ. T.,
LeinonenM.1987; Protective efficacy of monoclonal antibodies to class 1 and 3 outer membrane proteins of Neisseria meningitidis B: 15: PI. 16 in infant rat infection model. New prospects for vaccine development. Microbial Pathogenesis 3:261–268
SelanderR. K.,
CaugantD. A.,
OchmanH.,
MusserJ. M.,
GilmourM. N.,
WhittmanT. S.1986; Methods of multilocus enzyme electrophoresis for bacterial population genetics and sys-tematics. Applied and Environmental Microbiology 51:873884
SlawigB.1986; Antigen-spezifitat von Serum-Antikorpern in Bezug auf die Zelloberflache von Neisseria meningitidis der Serogruppe A. Freie Universitat, Fachbereich Biologie; Berlin: pp 1–114
SwansonJ.,
KingG.1978; Neisseria gonorrhoeae granulocyte interactions. In
BrooksC. F.
(ed) Immunobiology of Neisseria gonorrhoeae American Society for Microbiology; Washington DC: pp 221–226
TinsleyC. R.,
HeckelsJ. E.1986; Variation in the expression of pili and outer membrane protein by Neisseria meningitidis during the course of meningococcal infection. Journal of General Microbiology 132:2483–2490
Tsai FraschC. E.,
MoccaL. F.1981; Five structural classes of major outer membrane proteins in Neisseria meningitidis. Journal of Bacteriology 146:69–78
VanPuttenJ. M. P.,
LindersM. T.,
WeelJ. F. L.,
PoolmanJ. T.1987; Differential expression of Fe-repressible and growth-rate-sensitive proteins in Neisseria meningitidis and Neisseria gonorrhoeae. Antonie van Leeuwenhoek 53:557–564
VirjiM.,
HeckelsJ. E.1983; Antigenic cross-reactivity of Neisseria pili: investigations with type- and species-specific monoclonal antibodies. Journal of General Microbiology 129:2761–2768
VirjiM.,
HeckelsJ. E.,
WattP. J.1983; Monoclonal antibodies to gonococcal pili: studies on antigenic determinants on pili from variants of strain P9. Journal of General Microbiology 129:1965–1973
VirjiM.,
ZakK.,
HeckelsJ. E.1985; Use of monoclonal antibodies to detect common protein antigens present in outer membranes of Neisseria species. In
SchoolnikG. K.
(ed) The pathogenic neisseriae American Society for Microbiology; Washington DC: pp 276–280
WedegeE.,
MichaelsenT. E.1987; Human immunoglobin G subclass immune response to outer membrane antigens in meningococcal group B vaccine. Journal of Clinical Microbiology 25:1349–1353
ZollingerW. D.,
MandrellR. E.1980; Type-specific antigens of group A Neisseria meningitidis: lipopolysaccharide and heat-modifiable outer-membrane proteins. Infection and Immunity 28:451–458
ZollingerW. D.,
MandrellR. E.,
AltieriP.,
BermanS.,
LowenthalJ.,
ArtensteinM. S.1978; Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans. Journal of Infectious Diseases 137:728–739
ZollingerW. D.,
MandrellR. E.,
GriffissJ. M.,
AltieriP.,
BermanS.1979; Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. Journal of Clinical Investigation 63:836–848
ZollingerW. D.,
MoranE. E.,
ConnellyH.,
MandrellR. E.,
BrantR.1984; Monoclonal antibodies to serotype 2 and serotype 15 outer membrane proteins of Neisseria meningitidis and their use in serotyping. Infection and Immunity 46:260–266
ZollingerW. D.,
PenningtonC. L.,
ArtensteinM. S.1974; Human antibody response to three meningococcal outer membrane antigens: comparison by specific haemagglutination assay. Infection and Immunity 10:975–984